Spelbolaget avser att ta in nytt kapital genom en nyemission.
Framgångssagan fortsätter för New Wave som levererar ytterligare ett starkt kvartal.
Redeye comments on QleanAir’s Q1 figures, where sales were in line while profitability recovered sig...
Redeye shares its initial thoughts on FlexQube’s Q1 report, which was weaker than expected top-line-...
H2'23e Algo recovery increasingly likely '23e-'25e sales down 2-5% '23e-'24e EV/EBITDA of 19-9x Q1'...
Redeye saw a Q1 report showing sales slightly below our estimates in real terms, while costs were ge...
Redeye comments on Freemelt’s Q1 results which came in better than expected due to good cost control...
Redeye comments on Idogen following the company’s Q1 2023 report.
Sales SEK +0.7m and adj. EBIT +28% vs. ABGSCe Positive FCF due to reduction in receivables Restructu...
Redeye makes minor forecast adjustments following Bredband2’s Q1 2023 report, in which sales came in...
Redeye initiates coverage of Magle Chemoswed, a hybrid medtech/biotech company with a diverse array ...
Redeye returns with a review following BIMobject’s Q1 report which showed slow but steady progress.
Vow published its Q1 update on 9 May, posting a 14% beat to company-compiled consensus on the top li...
Solid org. growth of 12%, but a tad weaker profitability Adj.
Strong NWT sales, cash flow lags earnings NWT boosted by customers building inventory Share is tradi...
Delivering as expected in Q1 Lots to look forward to in 2023 P/NAV of 0.
2% PTP beat despite higher-than-expected restructuring costs Higher costs are of a one-off nature – ...
Obducat AB (publ) (”Obducat” eller ”Bolaget”) har under årets första kvartal fortsatt vunnit affärer...
ADDvise, som förvärvar bolag inom hälso- och sjukvård, har fått en flygande start på 2023.
En strategisk översyn av planerade kliniska prövningar har inletts.
